<DOC>
	<DOC>NCT02923154</DOC>
	<brief_summary>The purpose of this study is to investigate the efficacy, safety, tolerability and pharmacokinetics of multiple oral administration of MT-3995 in patients with NASH.</brief_summary>
	<brief_title>Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Subjects diagnosed with NASH before randomization Subjects who conducts diet or exercise therapy at the beginning of run in period. Subjects who has given full and adequate information of the protocol and with written informed consent Subjects with hepatic failure or previously diagnosed with hepatic cirrhosis Subjects with alcohol dependence or previously diagnosed with alcohol dependence Subjects with other chronic liver disease (e.g., primary sclerosing cholangitis, alcoholic liver damage, hemochromatosis, Wilson's disease) Presence, history, or family history of long QT syndrome or Torsades de Pointes Subjects with heart failure (New York Heart Association Class IIIIV)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>NASH</keyword>
</DOC>